87190-79-2
87190-79-2 結構式
基本信息
AzddMeC
3'-azido-2',3'-dideoxy-5-methylcytidine
3'-Azido-2',3'-dideoxy-4-deoxo-4-imino-5-methyluridine
物理化學性質(zhì)
| 報價日期 | 產(chǎn)品編號 | 產(chǎn)品名稱 | CAS號 | 包裝 | 價格 |
| 2026/06/05 | HY-105268 | 3'-疊氮基-2',3'-二脫氧-5-甲基胞苷 AzddMeC | 87190-79-2 | 1 mg | 954元 |
| 2026/06/05 | HY-105268 | 3'-疊氮基-2',3'-二脫氧-5-甲基胞苷 AzddMeC | 87190-79-2 | 5 mg | 2100元 |
| 2026/06/05 | HY-105268 | 3'-疊氮基-2',3'-二脫氧-5-甲基胞苷 AzddMeC | 87190-79-2 | 10 mM * 1 mLin DMSO | 2310元 |
常見問題列表
|
HIV-1 9 nM (EC 50 , Human PBM cells) |
HIV-1 6 nM (EC 50 , Human macrophages) |
AzddMeC (CS-92) is also effective against HIV-2 in lymphocytes. The replication of Friend murine virus is only weakly inhibited, and no effect is observed against HSV type 1 and type 2 and coxsackievirus B4. The interaction of the 5'-triphosphate of AzddMeC with HIV-1 reverse transcriptase indicated competitive inhibition (the inhibition constant, Kis, is 9.3 nM).
The pharmacokinetics of AzddMeC are characterized following intravenous and oral administration of 60 mg/kg of the compound to male rhesus monkeys. 3'-azido-3'-deoxythymidine (AZT) is a major metabolite of AzddMeC in monkeys. AzddMeC concentrations in serum declined rapidly in a biexponential fashion with the terminal half-life ranging from 0.5 to 1.3 hr. Renal excretion of unchanged nucleoside and metabolic deamination yielding AZT are the primary routes of AzddMeC clearance. The oral bioavailability is 26%.